

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**信銘生命科技集團有限公司**  
**Aceso Life Science Group Limited**  
*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 00474)**

**RESUMPTION OF TRADING**

Reference is made to the announcement of Aceso Life Science Group Limited (the “**Company**”) dated 30 June 2026 (the “**Announcement**”) in relation to, among other things, the delay in publication of the 2026 Annual Results. Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcement.

Following the publication of the 2026 Annual Results on 13 August 2026, application has been made by the Company to the Stock Exchange for the resumption of trading in the shares of the Company on the Stock Exchange with effect from 9:00 a.m. on 14 August 2026.

**Shareholders of the Company and potential investors are reminded to exercise caution when dealing in the shares or other securities of the Company.**

By Order of the Board  
**Aceso Life Science Group Limited**  
**Zhiliang Ou**  
*Executive Director*

Hong Kong, 13 August 2026

*As at the date of this announcement, the Board comprises two executive directors, namely Dr. Zhiliang Ou (J.P. (Australia)) and Mr. Fok Chi Tak; one non-executive director, namely Ms. Jiang Yang; and three independent non-executive directors, namely Mr. Chan Ming Sun Jonathan, Mr. Lam Kwan Sing and Mr. Mak Yiu Tong.*